Blair Wants UK To Be Leader In Stem Cells, Other Scientific Work May 29, 2002 By Nuala Moran No Comments
KS Biomedix Stops Development Of KSB302, Enters TransMID Deal May 29, 2002 By Nuala Moran No Comments
Ark Delays Initial Public Offering Due To Unfavorable Conditions May 22, 2002 By Nuala Moran No Comments LONDON - Ark Therapeutics Group plc postponed its initial public offering on the London Stock Market, blaming "unusually adverse market conditions." (BioWorld International)Read More
Enact Acquires Rights To Cytoxic, Prepares To File For Approvals May 22, 2002 By Nuala Moran No Comments
CeNeS Releases Positive Interim Results Of CNS5161 In Phase II May 22, 2002 By Nuala Moran No Comments
CeNeS Releases Positive Interim Results Of CNS5161 In Phase II May 22, 2002 By Nuala Moran No Comments
Enact Acquires Rights To Cytoxic, Prepares To File For Approvals May 22, 2002 By Nuala Moran No Comments
